Brought to you by 
Aspreva develops Roche's CellCept for autoimmune disorders
08 Feb 2006
Executive Summary
Specialty pharmaceuticals company Aspreva Pharmaceuticals licensed exclusive worldwide rights (excluding Japan) to develop and sell Roche's CellCept (mycophenolate mofetil) for all autoimmune disease applications.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Aspreva develops Roche's CellCept for autoimmune disorders
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice